BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bowring MG, Kucirka LM, Massie AB, Luo X, Cameron A, Sulkowski M, Rakestraw K, Gurakar A, Kuo I, Segev DL, Durand CM. Changes in Utilization and Discard of Hepatitis C-Infected Donor Livers in the Recent Era. Am J Transplant. 2017;17:519-527. [PMID: 27456927 DOI: 10.1111/ajt.13976] [Cited by in Crossref: 64] [Cited by in F6Publishing: 63] [Article Influence: 10.7] [Reference Citation Analysis]
Number Citing Articles
1 Yu M, Chen P, Dai C, Hu T, Huang C, Huang Y, Hung C, Lin C, Liu C, Liu C, Peng C, Lin H, Kao J, Chuang W. 2020 Taiwan consensus statement on the management of hepatitis C: Part (II) special populations. Journal of the Formosan Medical Association 2020;119:1135-57. [DOI: 10.1016/j.jfma.2020.04.002] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 12.0] [Reference Citation Analysis]
2 Ruck JM, Segev DL. Expanding deceased donor kidney transplantation: medical risk, infectious risk, hepatitis C virus, and HIV. Curr Opin Nephrol Hypertens 2018;27:445-53. [PMID: 30169460 DOI: 10.1097/MNH.0000000000000456] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 2.3] [Reference Citation Analysis]
3 Xie R, Huang S, Sun C, Zhu Z, Tang Y, Zhao Q, Guo Z, He X, Ju W. Deceased Donor Predictors for Pediatric Liver Allograft Utilization. Transplant Proc 2020;52:2901-8. [PMID: 32718748 DOI: 10.1016/j.transproceed.2020.05.010] [Reference Citation Analysis]
4 Van Pilsum Rasmussen SE, Seaman S, Brown D, Desai N, Sulkowski M, Segev DL, Durand CM, Sugarman J. Patient's Perspectives of Experimental HCV-Positive to HCV-Negative Renal Transplantation: Report from a Single Site. AJOB Empir Bioeth 2020;11:40-52. [PMID: 31618112 DOI: 10.1080/23294515.2019.1670277] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
5 Weinfurtner K, Reddy KR. Hepatitis C viraemic organs in solid organ transplantation. J Hepatol. 2021;74:716-733. [PMID: 33212088 DOI: 10.1016/j.jhep.2020.11.014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
6 Saab S, Kardashian A, Saggi S, Choi G, Agopian V, Tong MJ. Use of hepatitis C-positive grafts in hepatitis C-negative liver transplant recipients is cost effective. Clin Transplant 2018;32:e13383. [PMID: 30129981 DOI: 10.1111/ctr.13383] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
7 Kwong AJ, Wall A, Melcher M, Wang U, Ahmed A, Subramanian A, Kwo PY. Liver transplantation for hepatitis C virus (HCV) non-viremic recipients with HCV viremic donors. Am J Transplant. 2019;19:1380-1387. [PMID: 30378723 DOI: 10.1111/ajt.15162] [Cited by in Crossref: 66] [Cited by in F6Publishing: 61] [Article Influence: 16.5] [Reference Citation Analysis]
8 European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu.; European Association for the Study of the Liver. EASL Recommendations on Treatment of Hepatitis C 2018. J Hepatol. 2018;69:461-511. [PMID: 29650333 DOI: 10.1016/j.jhep.2018.03.026] [Cited by in Crossref: 905] [Cited by in F6Publishing: 751] [Article Influence: 226.3] [Reference Citation Analysis]
9 Chan S, Isbel NM, Hawley CM, Campbell SB, Campbell KL, Morrison M, Francis RS, Playford EG, Johnson DW. Infectious Complications Following Kidney Transplantation-A Focus on Hepatitis C Infection, Cytomegalovirus Infection and Novel Developments in the Gut Microbiota. Medicina (Kaunas) 2019;55:E672. [PMID: 31590269 DOI: 10.3390/medicina55100672] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
10 Sapisochin G, Bruix J. Liver transplantation for hepatocellular carcinoma: outcomes and novel surgical approaches. Nat Rev Gastroenterol Hepatol. 2017;14:203-217. [PMID: 28053342 DOI: 10.1038/nrgastro.2016.193] [Cited by in Crossref: 146] [Cited by in F6Publishing: 145] [Article Influence: 29.2] [Reference Citation Analysis]
11 Chacon MM, Adams AJ, Kassel CA, Markin NW. High-Risk and Hepatitis C-Positive Organ Donors: Current Practice in Heart, Lung, and Liver Transplantation. J Cardiothorac Vasc Anesth 2020;34:2492-500. [PMID: 31954619 DOI: 10.1053/j.jvca.2019.12.012] [Reference Citation Analysis]
12 Terrault NA, McCaughan GW, Curry MP, Gane E, Fagiuoli S, Fung JYY, Agarwal K, Lilly L, Strasser SI, Brown KA. International Liver Transplantation Society Consensus Statement on Hepatitis C Management in Liver Transplant Candidates. Transplantation. 2017;101:945-955. [PMID: 28437387 DOI: 10.1097/tp.0000000000001708] [Cited by in Crossref: 57] [Cited by in F6Publishing: 12] [Article Influence: 14.3] [Reference Citation Analysis]
13 Somerville L, Doucette K. Hepatitis C: Current Controversies and Future Potential in Solid Organ Transplantation. Curr Infect Dis Rep 2018;20:18. [PMID: 29789956 DOI: 10.1007/s11908-018-0625-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
14 Delman AM, Ammann AM, Shah SA. The current status of virus-positive liver transplantation. Curr Opin Organ Transplant 2021;26:160-7. [PMID: 33595981 DOI: 10.1097/MOT.0000000000000850] [Reference Citation Analysis]
15 Murag S, Dennis BB, Kim D, Ahmed A, Cholankeril G. Recent advances in liver transplantation with HCV seropositive donors. F1000Res 2019;8:F1000 Faculty Rev-2151. [PMID: 31942236 DOI: 10.12688/f1000research.20387.1] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
16 Kling CE, Limaye AP, Sibulesky L. Changing landscape of hepatitis C virus-positive donors. World J Hepatol 2017; 9(20): 905-906 [PMID: 28804573 DOI: 10.4254/wjh.v9.i20.905] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
17 Park H, Jung ES, Lee MH, Lee JM. Organ Donation from Donors with Hepatitis B or C in South Korea: A 2013-2017 Nationwide Data Analysis. Ann Transplant 2021;26:e928947. [PMID: 33927178 DOI: 10.12659/AOT.928947] [Reference Citation Analysis]
18 Trapero-marugán M, Little EC, Berenguer M. Stretching the boundaries for liver transplant in the 21st century. The Lancet Gastroenterology & Hepatology 2018;3:803-11. [DOI: 10.1016/s2468-1253(18)30213-9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 2.8] [Reference Citation Analysis]
19 Da BL, Ezaz G, Kushner T, Crismale J, Kakked G, Gurakar A, Dieterich D, Schiano TD, Saberi B. Donor Characteristics and Regional Differences in the Utilization of HCV-Positive Donors in Liver Transplantation. JAMA Netw Open 2020;3:e2027551. [PMID: 33275155 DOI: 10.1001/jamanetworkopen.2020.27551] [Reference Citation Analysis]
20 Daniel KE, Said A. Considerations When Treating Hepatitis C in a Cirrhotic Transplant Candidate. Curr Gastroenterol Rep. 2018;20:20. [PMID: 29623506 DOI: 10.1007/s11894-018-0626-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
21 Durand CM, Chattergoon MA. Bypassing the bottleneck: intentional hepatitis C transmission with organ transplant. J Clin Invest 2019;129:3038-40. [PMID: 31232703 DOI: 10.1172/JCI129982] [Reference Citation Analysis]
22 Durand CM, Bowring MG, Thomas AG, Kucirka LM, Massie AB, Cameron A, Desai NM, Sulkowski M, Segev DL. The Drug Overdose Epidemic and Deceased-Donor Transplantation in the United States: A National Registry Study. Ann Intern Med 2018;168:702-11. [PMID: 29710288 DOI: 10.7326/M17-2451] [Cited by in Crossref: 108] [Cited by in F6Publishing: 37] [Article Influence: 27.0] [Reference Citation Analysis]
23 Bushyhead D, Goldberg D. Use of Hepatitis C-Positive Donor Livers in Liver Transplantation. Curr Hepatol Rep 2017;16:12-7. [PMID: 28243573 DOI: 10.1007/s11901-017-0327-0] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
24 van Tilborg M, Maan R, van der Meer AJ, de Knegt RJ. Interferon-free antiviral therapy for chronic hepatitis C among patients in the liver transplant setting. Best Pract Res Clin Gastroenterol 2017;31:219-25. [PMID: 28624110 DOI: 10.1016/j.bpg.2017.04.006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
25 Shaffer AA, Durand CM. Solid Organ Transplantation for HIV-Infected Individuals. Curr Treat Options Infect Dis 2018;10:107-20. [PMID: 29977166 DOI: 10.1007/s40506-018-0144-1] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
26 Cannon RM, Locke JE, Orandi BJ, Anderson DJ, Davis EG, Mackelaite L, Dave H, Eng M, Jones CM. Impact of Donor Hepatitis C Virus on Kidney Transplant Outcomes for Hepatitis C-positive Recipients in the Direct-acting Antiviral Era: Time to Revise the Kidney Donor Risk Index? Transplantation 2020;104:1215-28. [PMID: 31517783 DOI: 10.1097/TP.0000000000002949] [Cited by in Crossref: 9] [Article Influence: 4.5] [Reference Citation Analysis]
27 Selzner N, Berenguer M. Should organs from hepatitis C-positive donors be used in hepatitis C-negative recipients for liver transplantation? Liver Transpl 2018;24:831-40. [DOI: 10.1002/lt.25072] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 5.8] [Reference Citation Analysis]
28 Martin EF. Paradigm Shift in Utilization of Livers from Hepatitis C-Viremic Donors into Hepatitis C Virus-Negative Patients. Clin Liver Dis 2021;25:195-207. [PMID: 33978579 DOI: 10.1016/j.cld.2020.08.009] [Reference Citation Analysis]
29 Pedersen MR, Tarlow BD, Mufti AR. CON: Patients With Decompensated Cirrhosis Listed for Liver Transplantation Should Be Treated Posttransplant. Clin Liver Dis (Hoboken) 2019;14:20-3. [PMID: 31391932 DOI: 10.1002/cld.789] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
30 Durand CM, Bowring MG, Brown DM, Chattergoon MA, Massaccesi G, Bair N, Wesson R, Reyad A, Naqvi FF, Ostrander D, Sugarman J, Segev DL, Sulkowski M, Desai NM. Direct-Acting Antiviral Prophylaxis in Kidney Transplantation From Hepatitis C Virus-Infected Donors to Noninfected Recipients: An Open-Label Nonrandomized Trial. Ann Intern Med 2018;168:533-40. [PMID: 29507971 DOI: 10.7326/M17-2871] [Cited by in Crossref: 164] [Cited by in F6Publishing: 61] [Article Influence: 41.0] [Reference Citation Analysis]
31 Crismale JF, Ahmad J. Expanding the donor pool: Hepatitis C, hepatitis B and human immunodeficiency virus-positive donors in liver transplantation. World J Gastroenterol 2019; 25(47): 6799-6812 [PMID: 31885421 DOI: 10.3748/wjg.v25.i47.6799] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
32 Shaffer AA, Thomas AG, Bowring MG, Van Pilsum Rasmussen SE, Cash A, Kucirka LM, Alqahtani SA, Gurakar A, Sulkowski MS, Cameron AM, Segev DL, Durand CM. Changes in practice and perception of hepatitis C and liver transplantation: Results of a national survey. Transpl Infect Dis 2018;20:e12982. [PMID: 30144258 DOI: 10.1111/tid.12982] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
33 Campos-Varela I, Agudelo EZ, Sarkar M, Roberts JP, Terrault NA. Use of a hepatitis C virus (HCV) RNA-positive donor in a treated HCV RNA-negative liver transplant recipient. Transpl Infect Dis 2018;20. [PMID: 29125670 DOI: 10.1111/tid.12809] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
34 Verna EC, Goldberg DS. Hepatitis C viremic donors for hepatitis C nonviremic liver transplant recipients: Ready for prime time?: Verna and Goldberg. Liver Transpl 2018;24:12-4. [DOI: 10.1002/lt.24985] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
35 Crismale JF, Khalid M, Bhansali A, De Boccardo G, Khaim R, Florman SS, Shapiro R, Schiano TD. Liver, simultaneous liver-kidney, and kidney transplantation from hepatitis C-positive donors in hepatitis C-negative recipients: A single-center study. Clin Transplant 2020;34:e13761. [PMID: 31808193 DOI: 10.1111/ctr.13761] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
36 Nagai S, Chau LC, Kitajima T, Yeddula S, Collins K, Rizzari M, Yoshida A, Abouljoud MS, Moonka D. A Share 21 model in liver transplantation: Impact on waitlist outcomes. Am J Transplant 2020;20:2184-97. [PMID: 32155314 DOI: 10.1111/ajt.15836] [Reference Citation Analysis]
37 Ting PS, Hamilton JP, Gurakar A, Urrunaga NH, Ma M, Glorioso J, King E, Toman LP, Wesson R, Garonzik-Wang J, Ottmann S, Philosophe B, Sulkowski M, Cameron AM, Durand CM, Chen PH. Hepatitis C-positive donor liver transplantation for hepatitis C seronegative recipients. Transpl Infect Dis 2019;21:e13194. [PMID: 31609520 DOI: 10.1111/tid.13194] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
38 Puigvehí M, Hashim D, Haber PK, Dinani A, Schiano TD, Asgharpour A, Kushner T, Kakked G, Tabrizian P, Schwartz M, Gurakar A, Dieterich D, Boffetta P, Friedman SL, Llovet JM, Saberi B. Liver transplant for hepatocellular carcinoma in the United States: Evolving trends over the last three decades. Am J Transplant 2020;20:220-30. [PMID: 31437349 DOI: 10.1111/ajt.15576] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
39 Wadei HM, Pungpapong S, Cortese C, Alexander MP, Keaveny AP, Yang L, Taner CB, Croome KP. Transplantation of HCV-infected organs into uninfected recipients: Advance with caution. Am J Transplant 2019;19:960-1. [PMID: 30372586 DOI: 10.1111/ajt.15152] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 4.5] [Reference Citation Analysis]
40 Ismail MS, Mohamed I, Polychronopoulou E, Goss JA, Kuo YF, Kanwal F, Jalal PK. Outcomes in the Era of Interferon-Free Direct-Acting Antiviral Therapy After Liver Transplantation in Patients with Hepatitis C Virus and Hepatocellular Carcinoma. J Hepatocell Carcinoma 2021;8:701-11. [PMID: 34235107 DOI: 10.2147/JHC.S309354] [Reference Citation Analysis]
41 Te H, Doucette K. Viral hepatitis: Guidelines by the American Society of Transplantation Infectious Disease Community of Practice. Clin Transplant 2019;33. [DOI: 10.1111/ctr.13514] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 7.7] [Reference Citation Analysis]
42 Bowring MG, Shaffer AA, Massie AB, Cameron A, Desai N, Sulkowski M, Garonzik-Wang J, Segev DL. Center-level trends in utilization of HCV-exposed donors for HCV-uninfected kidney and liver transplant recipients in the United States. Am J Transplant 2019;19:2329-41. [PMID: 30861279 DOI: 10.1111/ajt.15355] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 7.0] [Reference Citation Analysis]
43 Tabrizian P, Saberi B, Holzner ML, Rocha C, Kyung Jung Y, Myers B, Florman SS, Schwartz ME. Outcomes of transplantation for HBV- vs. HCV-related HCC: impact of DAA HCV therapy in a national analysis of >20,000 patients. HPB (Oxford) 2021:S1365-182X(21)01723-8. [PMID: 34955348 DOI: 10.1016/j.hpb.2021.11.018] [Reference Citation Analysis]
44 Çiftçibaşı Örmeci A, Yıldız Ç, Saberi B, Gürakar M, Şimşek C, Gürakar A. Usage of HCV viremic organs in liver transplantation to anti-HCV negative recipients: The current status and review of literature. Turk J Gastroenterol 2019;30:771-5. [PMID: 31530520 DOI: 10.5152/tjg.2019.18656] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
45 Metin O, Şimşek C, Gürakar A. Update on liver transplantation-newer aspects. Turk J Med Sci 2020;50:1642-50. [PMID: 32222125 DOI: 10.3906/sag-2002-17] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
46 Ariyamuthu VK, Sandikci B, Abdulrahim N, Hwang C, Macconmara MP, Parasuraman R, Atis A, Tanriover B. Trends in utilization of deceased donor kidneys based on hepatitis C virus status and impact of public health service labeling on discard. Transpl Infect Dis 2019;22. [DOI: 10.1111/tid.13204] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
47 White SL, Rawlinson W, Boan P, Sheppeard V, Wong G, Waller K, Opdam H, Kaldor J, Fink M, Verran D, Webster A, Wyburn K, Grayson L, Glanville A, Cross N, Irish A, Coates T, Griffin A, Snell G, Alexander SI, Campbell S, Chadban S, Macdonald P, Manley P, Mehakovic E, Ramachandran V, Mitchell A, Ison M. Infectious Disease Transmission in Solid Organ Transplantation: Donor Evaluation, Recipient Risk, and Outcomes of Transmission. Transplant Direct 2019;5:e416. [PMID: 30656214 DOI: 10.1097/TXD.0000000000000852] [Cited by in Crossref: 19] [Cited by in F6Publishing: 9] [Article Influence: 4.8] [Reference Citation Analysis]
48 Berenguer M, Agarwal K, Burra P, Manns M, Samuel D. The road map toward an hepatitis C virus-free transplant population. Am J Transplant 2018;18:2409-16. [PMID: 29935050 DOI: 10.1111/ajt.14976] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
49 Thuluvath PJ, Bruno DA, Alukal J, Satapathy SK, Thuluvath AJ, Zhang T. Use of HCV-Positive Livers in HCV-Negative Recipients. Am J Gastroenterol 2020;115:1045-54. [PMID: 32618655 DOI: 10.14309/ajg.0000000000000583] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
50 Shetty A, Buch A, Saab S. Use of Hepatitis C-Positive Liver Grafts in Hepatitis C-Negative Recipients. Dig Dis Sci 2019;64:1110-8. [PMID: 30560331 DOI: 10.1007/s10620-018-5404-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
51 Pawlotsky J, Negro F, Aghemo A, Berenguer M, Dalgard O, Dusheiko G, Marra F, Puoti M, Wedemeyer H. EASL recommendations on treatment of hepatitis C: Final update of the series☆. Journal of Hepatology 2020;73:1170-218. [DOI: 10.1016/j.jhep.2020.08.018] [Cited by in Crossref: 113] [Cited by in F6Publishing: 102] [Article Influence: 56.5] [Reference Citation Analysis]
52 Said A, Weiss M, Varhelyi A, Farago R, Ballweg C, Rice J, Agarwal P, Fernandez L, Foley D. Utilization of hepatitis C viremic donors for liver transplant recipients without hepatitis C. A veterans transplant center report. Transpl Infect Dis.  2020: e13466. [PMID: 32931616 DOI: 10.1111/tid.13466] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
53 Kling CE, Perkins JD, Landis CS, Limaye AP, Sibulesky L. Utilization of Organs From Donors According to Hepatitis C Antibody and Nucleic Acid Testing Status: Time for Change. Am J Transplant 2017;17:2863-8. [DOI: 10.1111/ajt.14386] [Cited by in Crossref: 47] [Cited by in F6Publishing: 47] [Article Influence: 9.4] [Reference Citation Analysis]
54 Levitsky J, Formica RN, Bloom RD, Charlton M, Curry M, Friedewald J, Friedman J, Goldberg D, Hall S, Ison M, Kaiser T, Klassen D, Klintmalm G, Kobashigawa J, Liapakis A, O'Conner K, Reese P, Stewart D, Terrault N, Theodoropoulos N, Trotter J, Verna E, Volk M. The American Society of Transplantation Consensus Conference on the Use of Hepatitis C Viremic Donors in Solid Organ Transplantation. Am J Transplant. 2017;17:2790-2802. [PMID: 28556422 DOI: 10.1111/ajt.14381] [Cited by in Crossref: 202] [Cited by in F6Publishing: 175] [Article Influence: 40.4] [Reference Citation Analysis]
55 Smibert OC, Paraskeva MA, Westall G, Snell G. An Update in Antimicrobial Therapies and Infection Prevention in Pediatric Lung Transplant Recipients. Paediatr Drugs 2018;20:539-53. [PMID: 30187362 DOI: 10.1007/s40272-018-0313-1] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
56 Halpern SE, Samoylova ML, Shaw BI, Kesseli SJ, Hartwig MG, Patel YA, McElroy LM, Barbas AS. Reexamining Risk Aversion: Willingness to Pursue and Utilize Nonideal Donor Livers Among US Donation Service Areas. Transplant Direct 2021;7:e742. [PMID: 34386579 DOI: 10.1097/TXD.0000000000001173] [Reference Citation Analysis]
57 Castaneda D, Gonzalez AJ, Alomari M, Tandon K, Zervos XB. From hepatitis A to E: A critical review of viral hepatitis. World J Gastroenterol 2021; 27(16): 1691-1715 [PMID: 33967551 DOI: 10.3748/wjg.v27.i16.1691] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
58 Chhatwal J, Samur S, Bethea ED, Ayer T, Kanwal F, Hur C, Roberts MS, Terrault N, Chung RT. Transplanting hepatitis C virus-positive livers into hepatitis C virus-negative patients with preemptive antiviral treatment: A modeling study. Hepatology. 2018;67:2085-2095. [PMID: 29222916 DOI: 10.1002/hep.29723] [Cited by in Crossref: 38] [Cited by in F6Publishing: 30] [Article Influence: 9.5] [Reference Citation Analysis]
59 Bethea ED, Samur S, Kanwal F, Ayer T, Hur C, Roberts MS, Terrault N, Chung RT, Chhatwal J. Cost Effectiveness of Transplanting HCV-Infected Livers Into Uninfected Recipients With Preemptive Antiviral Therapy. Clin Gastroenterol Hepatol. 2019;17:739-747.e8. [PMID: 30138735 DOI: 10.1016/j.cgh.2018.08.042] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 4.5] [Reference Citation Analysis]
60 Sáez-González E, Vinaixa C, San Juan F, Hontangas V, Benlloch S, Aguilera V, Rubín A, García M, Prieto M, López-Andujar R, Berenguer M. Impact of hepatitis C virus (HCV) antiviral treatment on the need for liver transplantation (LT). Liver Int 2018;38:1022-7. [PMID: 29105320 DOI: 10.1111/liv.13618] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
61 Awad SM, Taha M, Omar M, Khalil A. The implication of genetic variation in the complement C3 allotypes on the first-year allograft outcome after live donor liver transplantation. Transpl Immunol 2020;60:101294. [PMID: 32305505 DOI: 10.1016/j.trim.2020.101294] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
62 Parrish NF, Feurer ID, Matsuoka LK, Rega SA, Perri R, Alexopoulos SP. The Changing Face of Liver Transplantation in the United States: The Effect of HCV Antiviral Eras on Transplantation Trends and Outcomes. Transplant Direct 2019;5:e427. [PMID: 30882032 DOI: 10.1097/TXD.0000000000000866] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 4.3] [Reference Citation Analysis]
63 Cotter TG, Paul S, Sandıkçı B, Couri T, Bodzin AS, Little EC, Sundaram V, Charlton M. Increasing Utilization and Excellent Initial Outcomes Following Liver Transplant of Hepatitis C Virus (HCV)‐Viremic Donors Into HCV‐Negative Recipients: Outcomes Following Liver Transplant of HCV‐Viremic Donors. Hepatology 2019. [DOI: 10.1002/hep.30540] [Cited by in Crossref: 22] [Cited by in F6Publishing: 31] [Article Influence: 7.3] [Reference Citation Analysis]
64 Bowring MG, Kucirka LM, Massie AB, Ishaque T, Bae S, Shaffer AA, Garonzik Wang J, Sulkowski M, Desai N, Segev DL, Durand CM. Changes in Utilization and Discard of HCV Antibody-Positive Deceased Donor Kidneys in the Era of Direct-Acting Antiviral Therapy. Transplantation 2018;102:2088-95. [PMID: 29912046 DOI: 10.1097/TP.0000000000002323] [Cited by in Crossref: 21] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
65 Kapila N, Khalloufi KA, Flocco G, Menon KVN, Lindenmeyer C, Reino D, Vanatta JM, Ebaid S, Tzakis A, Zervos XB. Transplantation of HCV Viremic Livers into HCV Viremic Recipients Followed by Direct-acting Antiviral Therapy. J Clin Transl Hepatol 2019;7:122-6. [PMID: 31293911 DOI: 10.14218/JCTH.2019.00014] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]